Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

CNP-103 hos ungdom og voksne i alderen 12-35 år med nylig diagnostisert (innen 6 måneder) stadium 3 type 1 diabetes (T1D)

10. november 2026 oppdatert av: COUR Pharmaceutical Development Company, Inc.

En fase 1b/2a dobbeltblind, placebokontrollert studie for å evaluere sikkerheten, tolerabiliteten, farmakodynamikken og effekten av CNP-103 hos forsøkspersoner i alderen 12-35 år med nylig oppstått stadium 3 type 1-diabetes

This study is a Phase 1b/2a First-in-Human (FIH) clinical trial to assess the safety, tolerability, pharmacodynamics (PD), and efficacy of multiple ascending doses of CNP-103. The approximately 393-days study consists of a Screening Period (28 days), Treatment Period (90 days), and Post-Dose Evaluations (275 days).

Studieoversikt

Studietype

Intervensjonell

Registrering (Antatt)

72

Fase

  • Fase 2
  • Fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • Arizona
      • Tucson, Arizona, Forente stater, 85710
        • Rekruttering
        • Wake Research - Tucson
        • Ta kontakt med:
        • Hovedetterforsker:
          • David Alster
      • Tucson, Arizona, Forente stater, 85716
        • Rekruttering
        • Liver Institute PLLC
        • Ta kontakt med:
        • Hovedetterforsker:
          • Neda Ebrahimi
    • California
      • Newport Beach, California, Forente stater, 92663
        • Rekruttering
        • Hoag Memorial Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • David Ahn
        • Ta kontakt med:
      • San Diego, California, Forente stater, 92123
        • Rekruttering
        • Rady Children's Hospital San Diego
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Carla Demeterco-Berggren
      • Walnut Creek, California, Forente stater, 94598
    • Colorado
      • Aurora, Colorado, Forente stater, 80045
    • Florida
      • Fort Myers, Florida, Forente stater, 33907
        • Rekruttering
        • Southwest General Healthcare Center
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Orlando Fernandez
      • Gainesville, Florida, Forente stater, 32610
        • Rekruttering
        • University of Florida
        • Ta kontakt med:
        • Hovedetterforsker:
          • Timothy Foster
        • Ta kontakt med:
      • Hialeah, Florida, Forente stater, 33012
      • Jacksonville, Florida, Forente stater, 32207
        • Rekruttering
        • Nemours Children's Health
        • Hovedetterforsker:
          • Larry Fox
        • Ta kontakt med:
      • Miami, Florida, Forente stater, 33136
        • Rekruttering
        • University of Miami
        • Hovedetterforsker:
          • David Baidal
        • Ta kontakt med:
        • Ta kontakt med:
      • Miami, Florida, Forente stater, 33176
        • Rekruttering
        • DY Professional Research Center
        • Hovedetterforsker:
          • Soroush Aghigh
        • Ta kontakt med:
      • Tampa, Florida, Forente stater, 33612
        • Rekruttering
        • University of South Florida
        • Hovedetterforsker:
          • Henry Rodriguez
        • Ta kontakt med:
    • Georgia
      • Atlanta, Georgia, Forente stater, 30322
        • Rekruttering
        • Emory University
        • Ta kontakt med:
        • Hovedetterforsker:
          • Michael Hughes
      • Atlanta, Georgia, Forente stater, 30329
        • Rekruttering
        • Children's Healthcare of Atlanta
        • Hovedetterforsker:
          • Kristina Cossen
        • Ta kontakt med:
      • Atlanta, Georgia, Forente stater, 30318
        • Rekruttering
        • Atlanta Diabetes Association
        • Ta kontakt med:
        • Hovedetterforsker:
          • Carson Womack
    • Idaho
    • Illinois
      • Chicago, Illinois, Forente stater, 60611
      • Chicago, Illinois, Forente stater, 60611
        • Rekruttering
        • Ann & Robert H. Lurie Children's Hospital
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Naomi Fogel
      • Springfield, Illinois, Forente stater, 62702
        • Rekruttering
        • Southern Illinois University School of Medicine
        • Hovedetterforsker:
          • Gabriel Uwaifo
        • Ta kontakt med:
        • Ta kontakt med:
    • Indiana
      • Indianapolis, Indiana, Forente stater, 46202
        • Rekruttering
        • Riley Hospital for Children- Indiana University
        • Ta kontakt med:
        • Hovedetterforsker:
          • Linda DeMeglio
    • Maryland
      • Baltimore, Maryland, Forente stater, 21229
    • Massachusetts
      • Boston, Massachusetts, Forente stater, 02215
        • Rekruttering
        • Joslin Diabetes Center
        • Hovedetterforsker:
          • Jason Gaglia
        • Ta kontakt med:
    • Michigan
      • Ann Arbor, Michigan, Forente stater, 48109
        • Rekruttering
        • University of Michigan
        • Ta kontakt med:
        • Hovedetterforsker:
          • Elif Oral
        • Ta kontakt med:
      • Bloomfield Township, Michigan, Forente stater, 48302
        • Rekruttering
        • Embassy Research Network
        • Ta kontakt med:
        • Hovedetterforsker:
          • George Grunberger
    • Minnesota
      • Minneapolis, Minnesota, Forente stater, 55454
        • Rekruttering
        • University of Minnesota
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Antoinette Moran
    • Missouri
      • Kansas City, Missouri, Forente stater, 64108
        • Rekruttering
        • Children's Mercy Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Wayne Moore
      • St Louis, Missouri, Forente stater, 63110
        • Rekruttering
        • Washington University School of Medicine
        • Hovedetterforsker:
          • Janet McGill
        • Ta kontakt med:
    • New York
      • Buffalo, New York, Forente stater, 14203
        • Rekruttering
        • UBMD Pediatrics - University of Buffalo
        • Ta kontakt med:
        • Hovedetterforsker:
          • Lucy Mastrandrea
      • New York, New York, Forente stater, 10017
        • Rekruttering
        • NYU Langone Diabetes & Endocrine Associates
        • Ta kontakt med:
        • Hovedetterforsker:
          • Ramachandra Naik
      • New York, New York, Forente stater, 10016
        • Rekruttering
        • Hassenfield Children's Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Mary Gallagher
    • North Carolina
      • Durham, North Carolina, Forente stater, 27710
        • Rekruttering
        • Duke University
        • Ta kontakt med:
        • Hovedetterforsker:
          • Jennifer Green
      • Greenville, North Carolina, Forente stater, 27834
        • Rekruttering
        • Physicians East, PA
        • Hovedetterforsker:
          • Mark Warren
        • Ta kontakt med:
      • Raleigh, North Carolina, Forente stater, 27612
      • Smithfield, North Carolina, Forente stater, 27577
    • Ohio
      • Cleveland, Ohio, Forente stater, 44106
        • Rekruttering
        • University Hospitals Cleveland Medical Center
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Betul Hatipoglu
    • Tennessee
      • Chattanooga, Tennessee, Forente stater, 37411
        • Rekruttering
        • University Diabetes & Endocrine Consultants
        • Hovedetterforsker:
          • David Huffman
        • Ta kontakt med:
      • Memphis, Tennessee, Forente stater, 38105
        • Rekruttering
        • Le Bonhuer Children's
        • Ta kontakt med:
        • Hovedetterforsker:
          • Ramin Alemzadeh
    • Texas
      • Austin, Texas, Forente stater, 78749
      • Dallas, Texas, Forente stater, 75246
        • Rekruttering
        • M3 Wake Research - Dallas
        • Ta kontakt med:
        • Hovedetterforsker:
          • Carlos Arauz-Pacheco
      • Humble, Texas, Forente stater, 77346
      • San Antonio, Texas, Forente stater, 78229
      • Waxahachie, Texas, Forente stater, 75165
        • Rekruttering
        • TopLine Clinical, Inc
        • Ta kontakt med:
        • Hovedetterforsker:
          • Stephen Mueller
    • Washington
      • Seattle, Washington, Forente stater, 98101
      • Seattle, Washington, Forente stater, 98109
        • Rekruttering
        • University of Washington Diabetes Institute
        • Ta kontakt med:
          • Dori Khakpour
          • Telefonnummer: 206-945-4965
          • E-post: dorik@uw.edu
        • Hovedetterforsker:
          • Irl Hirsch

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

12 år til 35 år (Barn, Voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. Participants who are willing and able to provide Institutional Review Board (IRB) approved written informed consent and privacy language as per national regulations.

  2. Men and non-pregnant, non-breast-feeding women ages 12-35 years inclusive.

  3. Documented diagnosis of Stage 3 T1D within 180 days prior to study enrollment according to American Diabetes Association (ADA) criteria.

  4. Participants must be on standard of care diabetes management including insulin therapy as a routine and also consisting of a nutrition plan, regular exercise, or other relevant specialty care as required on a patient-by-patient basis.

  5. Participants with a peak stimulated C-peptide of >0.2 nmol/L measured from a screening mixed meal tolerance test (MMTT).

  6. Participants with an episode of diabetic ketoacidosis (DKA) must have a MMTT performed no sooner than 2 weeks after resolution of the DKA event to have a qualifying C-peptide reading.

  7. Participants on systemic corticosteroids or any medication used to treat the symptoms of T1D (other than insulin) must undergo a washout period of at least two weeks prior to enrollment and must agree to use a non-steroid alternative throughout the trial, if necessary, for any disorder requiring corticosteroids. In addition, participants must be on a stable dose of any other medications, other than insulin, for a minimum of 1 month prior to enrollment and must agree not to increase their dose from the Screening Visit through the End of Study Visit unless reviewed and approved by the medical monitor and the principal investigator.

  8. Female participants of non-childbearing potential (e.g., surgical sterilization, no menses for a year).

  9. Women of childbearing potential (WOCBP) who have agreed not to become pregnant during the study, have a negative pregnancy test at Screening Visit, and agree to use 1 highly effective form of birth control starting at initial screening and continuing throughout the entire study to Day 365.

  10. Female participants who agree to not breastfeed starting at initial Screening and throughout the entire study to Day 365.

  11. Female participants who agree to not donate ova, including autologous, starting at initial Screening and throughout the entire study to Day 365.

  12. Male participant and with a spouse or partner of childbearing potential, who themselves and their spouse or partner agree to practice an effective form of birth control as discussed with the study doctor or study staff starting at Screening and throughout the entire study to Day 365.

  13. Participants must weigh >35 kg at Screening for Cohort 1 (100 mg) and Cohort 2 (300 mg); participants must weigh >50 kg at Screening for Cohort 3 (600 mg).

  14. Body mass index (BMI):

    1. Participants 12-17 years: BMI Z-Score within 5th and 95th percentile based on participant's age (e.g., Baylor College of Medicine Age-based Pediatric Growth Reference Charts: BMI Z-Score and Percentile Calculator)
    2. Participants 18-35 years: 18.0-30.0 (not inclusive)

Exclusion Criteria:

  1. Participants unable to comply with prohibited medication outlined in the protocol.

  2. Exclusion of additional immunomodulation will be at the discretion of the Medical Monitor and study site Investigator.

  3. Participants with a history of tuberculosis or positive Quantiferon test.

  4. Participants who received vaccinations in the following time frame:

    1. Any live vaccine within 28 days prior to Screening.
    2. Any subunit vaccine within 14 days prior to Screening.
    3. Any COVID-19 vaccine series within 14 days prior to Screening.
    4. Any other planned vaccine starting 14 days prior to Screening and through study Day 90 and 1 week after. (Note: The annual influenza vaccine is not an exclusion criterion.)
  5. Known or suspected acute infection, including COVID-19 at the time of Screening or within 2 weeks prior to Screening. After confirmed recent COVID-19 infection, a minimum of 2 weeks of recovery post-acute infection is required.

  6. Participants with Screening laboratory test results that are outside the normal limits and considered by the Investigator to be clinically significant.

  7. Participants with positive test results for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, or human immunodeficiency virus (HIV) antigen/antibody as determined at Screening.

  8. Participants with a history of or currently active immune disorders other than T1D (including autoimmune disease) unless the condition, after discussion with the Medical Monitor, has been deemed to be acceptable for the participant's participation in this study.

  9. Participants with a clinical history of significant cardiovascular disease in the past 12 months.

  10. Participants with a complication or medical history of malignant tumor, other than basal cell or squamous cell carcinomas of the skin.

  11. Participants who, in the Investigator's opinion, will be unable to adhere to study visits and procedures.

  12. Participants who have received investigational therapy other than CNP-103 within 28 days or 5 half-lives, whichever is longer, prior to Screening.

  13. Participants with any known active condition which, in the Investigator's opinion, makes the participant unsuitable for study participation.

  14. Known sensitivity to any components of CNP-103.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Dobbelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Adult Cohort 1 (100 mg CNP-103)

Three (3) IV administrations of CNP-103 (100 mg) on Days 1, 8, and 90

CNP-103

Andre navn:
  • Behandling

0.9% sodium chloride for injection

Eksperimentell: Adult Cohort 2 (300 mg CNP-103)

Three (3) IV administrations of CNP-103 (300 mg) on Days 1, 8, and 90

CNP-103

Andre navn:
  • Behandling

0.9% sodium chloride for injection

Eksperimentell: Adult Cohort 3 (600 mg CNP-103)

Three (3) IV administrations of CNP-103 (600 mg) on Days 1, 8, and 90

CNP-103

Andre navn:
  • Behandling

0.9% sodium chloride for injection

Eksperimentell: Adolescent Cohort 1 (100 mg CNP-103)

Three (3) IV administrations of CNP-103 (100 mg) on Days 1, 8, and 90

CNP-103

Andre navn:
  • Behandling

0.9% sodium chloride for injection

Eksperimentell: Adolescent Cohort 2 (300 mg CNP-103)

Three (3) IV administrations of CNP-103 (300 mg) on Days 1, 8, and 90

CNP-103

Andre navn:
  • Behandling

0.9% sodium chloride for injection

Eksperimentell: Adolescent Cohort 3 (600 mg CNP-103)

Three (3) IV administrations of CNP-103 (600 mg) on Days 1, 8, and 90

CNP-103

Andre navn:
  • Behandling

0.9% sodium chloride for injection

Eksperimentell: Expansion Cohort

Dosing for the Expansion Cohort will be determined from Escalation Phase results

CNP-103

Andre navn:
  • Behandling

0.9% sodium chloride for injection

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Safety
Tidsramme: Day 1 Through Day 365

Frequency of Adverse Events (AEs) and Serious Adverse Events (SAEs), MedDRA 28.1 (CTCAE v. 5.0) or current

Day 1 Through Day 365
Immune Safety
Tidsramme: Day 1 Through Day 365

Serum Cytokines: IL-1β, TNF-α, IL-6, MCP-1, MIP-1α, IFN-γ, IL-4, IL-10

Day 1 Through Day 365

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

12. mai 2025

Primær fullføring (Antatt)

1. august 2027

Studiet fullført (Antatt)

1. desember 2027

Datoer for studieregistrering

Først innsendt

14. januar 2025

Først innsendt som oppfylte QC-kriteriene

14. januar 2025

Først lagt ut (Faktiske)

20. januar 2025

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

12. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

10. november 2026

Sist bekreftet

1. mars 2026

Mer informasjon

Begreper knyttet til denne studien

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere